Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in TRX?

Tissue Regenix rings changes after Cellright acquisition

Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
picture of human skeleton
Any shape you want with Cellright's matrix

Changes have taken place at regenerative med-tech Tissue Regenix PLC (LON:TRX) in the wake of its acquisition of Texas-based rival Cellright.

Steve Couldwell has been appointed as new chief executive having been on the board as a non-executive since 2013. Prior to that he worked more than 25 years in the pharmaceutical and medical device industry inlcding teh role of chief operating officer at Global Sanofi Biosurgery with responsibility for global strategy and execution.

READ: Tissue Regenix sees revenues double in ‘transformational’ first half

"Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7bn US bone graft and substitute market,” Couldwell said when appointed.

Cellright was acquired in 2017 for US$30mln in a move designed to lift Tissue to the front of the growing US market for regenerative medicine and bone grafts.

The Texas firm has a synergistic regenerative technology focused on bone that will complement Tissue’s own dCELL soft tissue platform.

“Furthermore, a broad development pipeline of innovative products, multiple established distribution channels and a state of the art US-based manufacturing facility will enable us to increase our growth and market penetration, cementing our presence in the key US market, as well as providing an opportunity to enter new geographies,” said Tissue.

Big beasts backs the deal

Woodford Asset Management took up almost 35% of the new shares issued, Invesco 31% and Perpetual 12.5% alongside a number of Tissue’s directors.

Tissue has developed skin graft, cartilage, ligament and valve replacement products based around its cell washing technology, which effectively eliminates the possibility of rejection by the body.

Cellright, meanwhile, has a technology that transforms human bone into a mouldable matrix that can be made into different shapes of malleable bone collagen scaffolds for a variety of graft purposes.

Thirteen products to add to the portfolio

In particular, Cellright’s products are guaranteed to be osteo-inductive, or form new bone, and retain regenerative properties post-implantation.

CellRight has launched 13 products since 2012 and will increase Tissue’s US sales by 2.5 times.

The San Antonio-based company posted revenues US$5.42mln in 2016 and underlying profits that year were US$1.58mln.

Access to US$1.7bn market

Research house Hardman said the acquisition of CellRight gives Tissue Regenix immediate access to the US$1.7bn North American bone graft and substitutes market.

“Although the market is dominated by the large players – Medtronic, De Puy Synthes, Stryker – there is opportunity for new entrants with differentiated offerings,” said analyst Martin Hall.

“In addition, the existing products and commercial relationships of CellRight will pave the way for Tissue’s entrance to the US orthopaedic soft tissue market, valued at US$2bn, with OrthoPure in 2018.”

Revenues up, losses down

Tissue saw revenues double in the first half of the year, driven by a strong performance of its GBM-V multi-tissue bank and higher sales of its DermaPure wound treatments.

Total revenues at the medical devices firm grew 118% in the six months ended 30 June to £1.37mln (H1 2016: £631,000).

The increased revenues helped Tissue to narrow its loss after tax to £4.77mln (H1 2016: £5.16mln).

In August, after period end, Tissue raised £40mln from investors, of which £25mln was used to complete the acquisition of CellRight.

At 8.8p, Tissue is valued at £102mln.

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

February 01 2018
December 21 2017
November 30 2017
November 30 2017
November 01 2017
October 17 2017
September 27 2017
September 07 2017
September 04 2017

Related Articles

January 18 2018
Regulatory sign-off fires starting pistol on the commercial launch in Europe, Africa, EU Medical Devices Directive awarded CE IVD certification, molecular diagnostics, Europe, Africa, Sysmex
Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 05 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.
Regeneus: Access latest PPT from Proactive's CEO Sessions
June 18 2017
John Martin discussed regenerative medicine with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use